Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

100721

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Osteoporosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much from the publich purse has been spent on research into osteoporosis in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211732
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

100729

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Osteoporosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many (a) men under the age of 18, (b) women under the age of 18, (c) men between the ages of 18 and 60, (d) women between the ages of 18 and 60, (e) men over the age of 60 and (f) women over the age of 60 have been diagnosed with osteoporosis in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211737
	answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>The provision of fracture liaison services (FLS) and falls services is a matter for local clinical commissioning groups (CCGs) and data on numbers is not collected centrally. NHS England advises that it is aware that provision of good FLS is not uniform across the country and is working with CCGs to support them to develop appropriate local services. It also advises that the FLS model recommended by the International Osteoporosis Foundation and the National Osteoporosis society is recognised as best practice and is being promoted. In addition to this, the guidance from the National Institute for Health and Care Excellence (NICE) ‘Falls: assessment and prevention of falls in older people’ sets out best practice for clinicians on the management of patients aged 65 and over who are susceptible to falls.</p><p> </p><p> </p><p> </p><p>Regarding the cost to the National Health Service of treating fractures attributable to osteoporosis, whilst programme budgeting data provides figures for annual NHS spend on musculoskeletal services in England, the cost of treating individual musculoskeletal conditions, such as osteoporosis or specific services such as FLS, is not available as part of this.</p><p> </p><p> </p><p> </p><p>Information concerning the number of people affected by osteoporosis in each of the last five years is not collected. NICE estimates that over 300,000 patients present with fragility fractures to hospitals in the United Kingdom each year.</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 211728 211736 211738 211740 question first answered 30/10/2014 16:37:15 answering member 1439 label Biography information for Norman Lamb
	tabling member	4026 label Biography information for Liz Kendall

100734

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Osteoporosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much was spent on campaigns intended to raise public awareness of osteoporosis and its symptoms in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211739
	answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>In the last five years there has been no budget allocated for specific osteoporosis national campaigns.</p><p> </p><p> </p><p> </p><p>Since April 2013 Public Health England’s marketing campaign investment approach has been to allocate budget against activity which has the greatest scope to deliver the key public health outcomes. This is based on lifestage rather than disease specific approach.</p><p> </p><p> </p><p> </p><p>More details of the 2014-2017 marketing campaign strategy can be found at</p><p> </p><p> </p><p> </p><p><a href="https://www.gov.uk/government/publications/public-health-england-marketing-strategy-2014-to-2017" target="_blank">https://www.gov.uk/government/publications/public-health-england-marketing-strategy-2014-to-2017</a></p><p> </p><p> </p><p> </p><p>There is a considerable amount of information about osteoporosis on NHS Choices website. However it is not possible to calculate the monetary value of this content.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 30/10/2014 16:41:33 answering member 3918 label Biography information for Jane Ellison
	tabling member	4026 label Biography information for Liz Kendall

229257

	registered interest
	date	23/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Osteoporosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many finished hospital admission episodes with a primary or secondary diagnosis of fractures attributable to osteoporosis there were amongst (a) women under, (b) women over, (c) men under and (d) men over the age of 50 in 2013-14.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	228838
	answer	answer is ministerial correction date of answer 26/03/2015 answer text <p>The following table provides a count of finished admission episodes where there was a primary or secondary diagnosis of fractures attributable to osteoporosis amongst men, women and genders not specified for the age groups requested for the period 2013-14.</p><p> </p><p><strong> </strong></p><p> </p><table><tbody><tr><td colspan="3"><p>Women</p></td><td colspan="3"><p>Men</p></td><td colspan="3"><p>Unknown gender</p></td></tr><tr><td><p>Aged under 50</p></td><td><p>Aged above 50</p></td><td><p>Unknown age</p></td><td><p>Aged under 50</p></td><td><p>Aged above 50</p></td><td><p>Unknown age</p></td><td><p>Aged under 50</p></td><td><p>Aged above 50</p></td><td><p>Unknown age</p></td></tr><tr><td><p>252</p></td><td><p>11,142</p></td><td><p>15</p></td><td><p>237</p></td><td><p>3,232</p></td><td><p>8</p></td><td><p>-</p></td><td><p>3</p></td><td><p>-</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p><em>Notes:</em></p><p> </p><p> </p><p> </p><p>1. A finished consultant episode (FCE) is a continuous period of admitted patient care under one consultant within one healthcare provider. FCEs are counted against the year in which they end. Figures do not represent the number of different patients, as a person may have more than one episode of care within the same stay in hospital or in different stays in the same year.</p><p> </p><p> </p><p> </p><p>2. The number of episodes where this diagnosis was recorded in any of the 20 (14 from 2002-03 to 2006-07 and 7 prior to 2002-03) primary and secondary diagnosis fields in a Hospital Episode Statistics (HES) record. Each episode is only counted once, even if the diagnosis is recorded in more than one diagnosis field of the record.</p><p> </p><p><strong> </strong></p><p> </p><p><em>Source:</em> Hospital Episodes Statistics (HES) Health and Social Care Information Centre.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 26/03/2015 12:53:05 answering member 1439 label Biography information for Norman Lamb
	tabling member	4026 label Biography information for Liz Kendall

451119

	registered interest
	date	08/02/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Osteoporosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what is the average waiting time for a result to be given of a DEXA bone density scan in each NHS region in England; and what assessment they have made of the average waiting time for such results in (1) Scotland, and (2) Wales.
	tabling member printed	Baroness Quin
	uin	HL5985
	answer	answer is ministerial correction date of answer 11/02/2016 answer text <p>Data are not collected on the average waiting time for a result to be given for a dual energy X-ray absorptiometry (DEXA) scan. Data are collected on the average waiting time from referral to test, and these are shown in the following table for the four NHS England commissioning regions for most recent period, which is November 2015. Health is a devolved matter in Scotland and Wales.</p><p> </p><p>Table: average median waiting times in weeks for a DEXA scan from referral by NHS England commissioning region, November 2015</p><p> </p><table><tbody><tr><td><p>Region</p></td><td><p>Number of weeks</p></td></tr><tr><td><p>North of England</p></td><td><p>2.1</p></td></tr><tr><td><p>Midlands and East of England</p></td><td><p>1.7</p></td></tr><tr><td><p>London</p></td><td><p>1.8</p></td></tr><tr><td><p>South of England</p></td><td><p>1.8</p></td></tr><tr><td><p>England</p></td><td><p>1.9</p></td></tr></tbody></table><p> </p><p><strong> </strong></p> answering member printed Lord Prior of Brampton question first answered 11/02/2016 13:18:56 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	518 label Biography information for Baroness Quin

65724

	registered interest
	date	03/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Osteoporosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, which NHS trusts offer a screening programme for osteoporosis.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	204002
	answer	answer is ministerial correction date of answer 08/07/2014 answer text <p>The UK National Screening Committee (UK NSC) advises Ministers and the National Health Service in all four countries about all aspects of screening policy and supports implementation.</p><p> </p><p>The UK NSC has reviewed the evidence for screening for osteoporosis in postmenopausal women and recommended that screening should not be offered. The UK NSC will review the evidence for screening again in 2016-17 as part of its three yearly review policy cycle.</p><p><strong> </strong></p><p>A preferred approach is to target higher risk groups (post-menopausal women, those on long term steroid use and after a first fracture). Prevention, assessment and treatment is covered in National Institute for Health and Clinical Excellence guidelines as follows:</p><p> </p><p><a href="http://pathways.nice.org.uk/pathways/osteoporosis" target="_blank">http://pathways.nice.org.uk/pathways/osteoporosis</a></p><p> </p><p>www.nice.org.uk/guidance/TA160</p><p> </p><p><a href="http://www.nice.org.uk/guidance/TA161" target="_blank">www.nice.org.uk/guidance/TA161</a></p><p> </p><p><a href="http://www.nice.org.uk/guidance/CG146" target="_blank">www.nice.org.uk/guidance/CG146</a></p><p> </p><p>There is patient information on the management of and living with osteoporosis on NHS Choices website:</p><p> </p><p>www.nhs.uk/Conditions/Osteoporosis/Pages/Introduction.aspx</p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 08/07/2014 14:46:31 answering member 1439 label Biography information for Norman Lamb
	tabling member	4036 label Biography information for Luciana Berger

66083

	registered interest
	date	07/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Osteoporosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what proportion of NHS trusts offer a screening programme of osteoporosis to reduce falls and fractures.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	204311
	answer	answer is ministerial correction date of answer 10/07/2014 answer text <p>The UK National Screening Committee (UK NSC) advises Ministers and the National Health Service in all four countries about all aspects of screening policy and supports implementation.</p><p> </p><p>The UK NSC has reviewed the evidence for screening for osteoporosis in postmenopausal women and recommended that screening should not be offered. The UK NSC will review the evidence for screening again in 2016-17 as part of its three yearly review policy cycle.</p><p><strong> </strong></p><p>A preferred approach is to target higher risk groups (post-menopausal women, those on long term steroid use and after a first fracture). Prevention, assessment and treatment is covered in National Institute for Health and Clinical Excellence guidelines as follows:</p><p> </p><p><a href="http://pathways.nice.org.uk/pathways/osteoporosis" target="_blank">http://pathways.nice.org.uk/pathways/osteoporosis</a></p><p> </p><p>www.nice.org.uk/guidance/TA160</p><p> </p><p>www.nice.org.uk/guidance/TA161</p><p> </p><p>www.nice.org.uk/guidance/CG146</p><p> </p><p>There is patient information on the management of and living with osteoporosis on the NHS Choices website:</p><p> </p><p>www.nhs.uk/Conditions/Osteoporosis/Pages/Introduction.aspx</p><p><strong> </strong></p><p><strong> </strong></p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 10/07/2014 13:59:13 answering member 1439 label Biography information for Norman Lamb
	tabling member	4036 label Biography information for Luciana Berger

800466

	registered interest
	date	04/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Osteoporosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they intend to ensure that women over 60 years old are routinely offered bone density scans to ascertain bone health.
	tabling member printed	Baroness Quin
	uin	HL3853
	answer	answer is ministerial correction date of answer 14/12/2017 answer text <p>Fracture liaison services (FLS) provide secondary prevention for fragility fractures. These services identify patients in secondary and/or primary care who have suffered a fragility fracture and assess the patient’s risk of future fragility fracture in a timely fashion. A FLS then provides advice and/or therapy to reduce that risk.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) evidence based guideline <em>Osteoporosis: assessing the risk of fragility fracture</em>, updated in February 2017, sets out best practice on management of fracture risk in patients with osteoporosis. A copy of the guideline is attached. The guidance recommends that clinicians consider assessment of fracture risk in all women aged 65 years and over and all men aged 75 years and over. Women aged less than 65 years and men aged less than 75 years should be considered for assessment in the presence of certain risk factors, such as a family history of hip fracture or low body mass index.</p><p> </p><p>Regarding bone density scanning, NICE recommends it be considered after patients have first been assessed using a validated risk assessment tool, such as FRAX, which clinicians can use to evaluate the 10-year probability of bone fracture risk in patient. The guidance also recommends other circumstances where bone density scanning should be considered, including for patients who are to undergo treatment which may affect bone density, such as certain treatments for breast or prostate cancer.</p><p> </p><p> </p> answering member printed Lord O'Shaughnessy grouped question UIN HL3852 question first answered 14/12/2017 15:01:14 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name osteoporosis-assessing-the-risk-of-fragility-fracture-pdf-35109574194373.pdf title Osteoporosis
	tabling member	518 label Biography information for Baroness Quin